Wall Street Analysts Are Bullish on Top Services Picks

There’s a lot to be optimistic about in the Services sector as 3 analysts just weighed in on Genesco Inc (NYSE: GCO), JJill Inc (NASDAQ: JILL) and Interpace Diagnostics Group Inc (NASDAQ: IDXG) with bullish sentiments.

Genesco Inc (NYSE: GCO)

Jefferies analyst Janie Stichter reiterated a Buy rating on Genesco Inc (NYSE: GCO) yesterday and set a price target of $48. The company’s shares closed yesterday at $38.95.

According to TipRanks.com, Stichter is a 2-star analyst with an average return of 5.4% and a 66.7% success rate. Stichter covers the Services sector, focusing on stocks such as Lululemon Athletica Inc, Abercrombie Fitch, and American Eagle.

Genesco Inc has an analyst consensus of Moderate Buy, with a price target consensus of $40.67.

JJill Inc (NASDAQ: JILL)

In a report released yesterday, Randal Konik from Jefferies reiterated a Buy rating on JJill Inc (NASDAQ: JILL), with a price target of $10. The company’s shares closed yesterday at $4.82, close to its 52-week low of $4.74.

According to TipRanks.com, Konik is a 4-star analyst with an average return of 4.7% and a 54.4% success rate. Konik covers the Services sector, focusing on stocks such as Lululemon Athletica Inc, Eros International Plc, and Abercrombie Fitch.

JJill Inc has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.

Interpace Diagnostics Group Inc (NASDAQ: IDXG)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Interpace Diagnostics Group Inc (NASDAQ: IDXG) today and set a price target of $3. The company’s shares closed yesterday at $1.10, close to its 52-week low of $0.72.

McCarthy wrote:

“Interpace reported 4Q17 with revenue of $4.4M, up 4% sequentially and 40% y/ y. Gross margin expanded to 53.7%, from 49.2% y/y. While the company did not provide a breakdown of revenue by product (ThyGenX/ThyraMIR, PancraGEN), management did say it’s near a 50:50 split. The company reported a net loss of $5M and ended the period with $15.2M in cash.”

According to TipRanks.com, McCarthy is a 3-star analyst with an average return of 2.6% and a 37.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Stellar Biotechnologies, Inc., and ImmunoCellular Therapeutics.

Currently, the analyst consensus on Interpace Diagnostics Group Inc is Moderate Buy and the average price target is $3, representing a 172.7% upside.

In a report issued on March 8, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $3 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.